Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis

Open access
Wang, Ji, Ye, Chenyang, Chen, Cong, Xiong, Hanchu, Xie, Binbin, Zhou, Jichun, Chen, Yongxia, Zheng, Shu, Wang, Linbo·2017·Oncotarget

Abstract

// Ji Wang 1, 2, * , Chenyang Ye 3, * , Cong Chen 1, 2 , Hanchu Xiong 1, 2 , Binbin Xie 1, 2 , Jichun Zhou 1, 2 , Yongxia Chen 1, 2 , Shu Zheng 3, 4 , Linbo Wang 1, 2 1 Department of Surgical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China 2 Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, Zhejiang, 310016, China 3 Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China 4 Reseach Center for Air Pollution and Health, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China * These authors contributed equally to this work Correspondence to: Linbo Wang, email: linbo.wang@aliyun.com Shu Zheng, email: zhengshu@zju.edu.cn Keywords: GLUT1, solid tumors, prognosis, overall survival, disease-free survival Received: November 17, 2016 Accepted: January 26, 2017 Published: February 07, 2017 ABSTRACT Glucose transporter 1 (GLUT1), the uniporter protein encoded by the SLC2A1 gene, is a key rate-limiting factor in the transport of glucose in cancer cells, and frequently expressed in a significant proportion of human cancers. Numerous studies have reported paradoxical evidence of the relationship between GLUT1 expression and prognosis in solid human tumors. To address this discrepancy, we conducted a thorough search of Pubmed and Web of Science for studies evaluating the expression of GLUT1 and overall survival (OS) and disease-free survival (DFS) in patients with solid cancer from 1993 to April 2016. Data from published researches were extracted and computed into odds ratio (OR). A total of 26 studies including 2948 patients met our search criteria and were evaluated. Overexpression of GLUT1 was found to significantly correlate with poor 3-year OS (OR: 2.86; 95% CI, 1.90–4.32, P < 0.00001) and 5-year OS (OR: 2.52; 95% CI, 1.75–3.61, P < 0.00001) of solid tumors. Similar results were observed when analysis of DFS was performed. Subgroup analysis revealed that elevated GLUT1 expression was associated with worse prognosis of oral squamous cell carcinoma and breast cancer. Taken together, overexpression of GLUT1 is correlated with poor survival in most solid tumors, suggesting that the expression status of GLUT1 is a vital prognostic indicator and promising therapeutic target in solid tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.15171

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 205

Metadata

Authors
Wang, J., Ye, C., Chen, C., Xiong, H., Xie, B., Zhou, J., Chen, Y., Zheng, S., & Wang, L.
Venue
Oncotarget
Published
2017-02-07
Volume
8
Issue
10
Pages
16875-16886
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2587331820
Cited by
205
References
6
FWCI
1.90
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.18632/oncotarget.15171
The paper
Wang, J., Ye, C., Chen, C., Xiong, H., Xie, B., Zhou, J., Chen, Y., Zheng, S., & Wang, L. (2017). Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. https://doi.org/10.18632/oncotarget.15171

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.